Allogeneic tumor cell vaccines

References

• Sherr CJ. Cancer cell cycles. Science 1996; 274:1672 - 7; http://dx.doi.org/10.1126/science.274.5293.1672; PMID: 8939849
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001; 1:222 - 31; http://dx.doi.org/10.1038/35106065; PMID: 11902577
   PubMed Web of Science ®Google Scholar
• Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411:342 - 8; http://dx.doi.org/10.1038/35077213; PMID: 11357141
   PubMed Web of Science ®Google Scholar
• Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004; 432:307 - 15; http://dx.doi.org/10.1038/nature03098; PMID: 15549092
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21:137 - 48; http://dx.doi.org/10.1016/j.immuni.2004.07.017; PMID: 15308095
   PubMed Web of Science ®Google Scholar
• Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 2007; 121:1 - 14; http://dx.doi.org/10.1111/j.1365-2567.2007.02587.x; PMID: 17386080
   PubMed Web of Science ®Google Scholar
• Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007; 117:1137 - 46; http://dx.doi.org/10.1172/JCI31405; PMID: 17476343
   PubMed Web of Science ®Google Scholar
• Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 2001; 83:117 - 58; http://dx.doi.org/10.1016/S0065-230X(01)83005-0; PMID: 11665717
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002; 2:850 - 61; http://dx.doi.org/10.1038/nrc928; PMID: 12415255
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 2008; 18:11 - 8; http://dx.doi.org/10.1016/j.gde.2007.12.007; PMID: 18308558
   PubMed Web of Science ®Google Scholar
• Vallejo R, Hord ED, Barna SA, Santiago-Palma J, Ahmed S. Perioperative immunosuppression in cancer patients. J Environ Pathol Toxicol Oncol 2003; 22:139 - 46; http://dx.doi.org/10.1615/JEnvPathToxOncol.v22.i2.70; PMID: 14533877
   PubMedGoogle Scholar
• Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL. 2011: the immune hallmarks of cancer. Cancer Immunol Immunother 2011; 60:319 - 26; http://dx.doi.org/10.1007/s00262-010-0968-0; PMID: 21267721
   PubMed Web of Science ®Google Scholar
• Ringdén O, Le Blanc K. Allogeneic hematopoietic stem cell transplantation: state of the art and new perspectives. APMIS 2005; 113:813 - 30; http://dx.doi.org/10.1111/j.1600-0463.2005.apm_336.x; PMID: 16480452
   PubMed Web of Science ®Google Scholar
• Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 2005; 65:8059 - 64; http://dx.doi.org/10.1158/0008-5472.CAN-05-1797; PMID: 16166275
   PubMed Web of Science ®Google Scholar
• Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006; 25:315 - 22; http://dx.doi.org/10.1007/s10555-006-9001-7; PMID: 16967326
   PubMed Web of Science ®Google Scholar
• Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M, Vile RG. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 1998; 4:581 - 7; http://dx.doi.org/10.1038/nm0598-581; PMID: 9585232
   PubMed Web of Science ®Google Scholar
• Tan T-T, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol 2007; 19:209 - 16; http://dx.doi.org/10.1016/j.coi.2007.01.001; PMID: 17276050
   PubMed Web of Science ®Google Scholar
• Colombo MP, Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now?. Immunol Today 1994; 15:48 - 51; http://dx.doi.org/10.1016/0167-5699(94)90131-7; PMID: 8155261
   PubMedGoogle Scholar
• Moingeon P. Cancer vaccines. Vaccine 2001; 19:1305 - 26; http://dx.doi.org/10.1016/S0264-410X(00)00372-8; PMID: 11163653
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366:883 - 92; http://dx.doi.org/10.1056/NEJMoa1113205; PMID: 22397650
   PubMed Web of Science ®Google Scholar
• Russnes HG, Navin N, Hicks J, Borresen-Dale A-L. Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest 2011; 121:3810 - 8; http://dx.doi.org/10.1172/JCI57088; PMID: 21965338
   PubMed Web of Science ®Google Scholar
• Copier J, Dalgleish A. Overview of tumor cell-based vaccines. Int Rev Immunol 2006; 25:297 - 319; http://dx.doi.org/10.1080/08830180600992472; PMID: 17169778
   PubMed Web of Science ®Google Scholar
• Ueda R, Shiku H, Pfreundschuh M, Takahashi T, Li LTC, Whitmore WF, Oettgen HF, Old LJ. Cell surface antigens of human renal cancer defined by autologous typing. J Exp Med 1979; 150:564 - 79; http://dx.doi.org/10.1084/jem.150.3.564; PMID: 479762
   PubMed Web of Science ®Google Scholar
• Hrouda D, Todryk SM, Perry MJA, Souberbielle BE, Kayaga J, Kirby RS, Dalgleish AG. Allogeneic whole-tumour cell vaccination in the rat model of prostate cancer. BJU Int 2000; 86:742 - 8; http://dx.doi.org/10.1046/j.1464-410x.2000.00887.x; PMID: 11069388
   PubMed Web of Science ®Google Scholar
• Knight BC, Souberbielle BE, Rizzardi GP, Ball SE, Dalgleish AG. Allogeneic murine melanoma cell vaccine: a model for the development of human allogeneic cancer vaccine. Melanoma Res 1996; 6:299 - 306; http://dx.doi.org/10.1097/00008390-199608000-00004; PMID: 8873049
   PubMed Web of Science ®Google Scholar
• Katagiri T, Shiobara S, Nakao S, Wakano M, Muranaka E, Kuba N, Furukawa T, Tsukada J, Takeda H, Aizawa Y, et al. Mismatch of minor histocompatibility antigen contributes to a graft-versus-leukemia effect rather than to acute GVHD, resulting in long-term survival after HLA-identical stem cell transplantation in Japan. Bone Marrow Transplant 2006; 38:681 - 6; http://dx.doi.org/10.1038/sj.bmt.1705506; PMID: 16980988
   PubMed Web of Science ®Google Scholar
• de Gruijl TD, van den Eertwegh AJM, Pinedo HM, Scheper RJ. Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother 2008; 57:1569 - 77; http://dx.doi.org/10.1007/s00262-008-0536-z; PMID: 18523771
   PubMed Web of Science ®Google Scholar
• Deacon DH, Hogan KT, Swanson EM, Chianese-Bullock KA, Denlinger CE, Czarkowski AR, Schrecengost RS, Patterson JW, Teague MW, Slingluff CL Jr.. The use of gamma-irradiation and ultraviolet-irradiation in the preparation of human melanoma cells for use in autologous whole-cell vaccines. BMC Cancer 2008; 8:360; http://dx.doi.org/10.1186/1471-2407-8-360; PMID: 19055839
   PubMed Web of Science ®Google Scholar
• Li J, King AV, Stickel SL, Burgin KE, Zhang X, Wagner TE, Wei Y. Whole tumor cell vaccine with irradiated S180 cells as adjuvant. Vaccine 2009; 27:558 - 64; http://dx.doi.org/10.1016/j.vaccine.2008.11.014; PMID: 19027812
   PubMed Web of Science ®Google Scholar
• Sharma A, Bode B, Wenger RH, Lehmann K, Sartori AA, Moch H, Knuth A, Boehmer Lv, Broek Mv. γ-Radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PLoS One 2011; 6:e28217; http://dx.doi.org/10.1371/journal.pone.0028217; PMID: 22140550
   PubMed Web of Science ®Google Scholar
• Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P, Zitvogel L, Kroemer G. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 2007; 14:1848 - 50; http://dx.doi.org/10.1038/sj.cdd.4402201; PMID: 17657249
   PubMed Web of Science ®Google Scholar
• Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: The GVAX (TM) vaccine for prostate cancer. Urologic Oncology-Seminars and Original Investigations 2006; 24:419 - 24; http://dx.doi.org/10.1016/j.urolonc.2005.08.021
   PubMed Web of Science ®Google Scholar
• Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002; 2:227 - 38; http://dx.doi.org/10.1038/nri774; PMID: 12001994
   PubMed Web of Science ®Google Scholar
• Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 2007; 18:226 - 32; http://dx.doi.org/10.1093/annonc/mdl158; PMID: 17116643
   PubMed Web of Science ®Google Scholar
• Satoh E, Naganuma H, Sasaki A, Nagasaka M, Ogata H, Nukui H. Effect of irradiation on transforming growth factor-beta secretion by malignant glioma cells. J Neurooncol 1997; 33:195 - 200; http://dx.doi.org/10.1023/A:1005791621265; PMID: 9195490
   PubMed Web of Science ®Google Scholar
• Klopp AH, Spaeth EL, Dembinski JL, Woodward WA, Munshi A, Meyn RE, Cox JD, Andreeff M, Marini FC. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res 2007; 67:11687 - 95; http://dx.doi.org/10.1158/0008-5472.CAN-07-1406; PMID: 18089798
   PubMed Web of Science ®Google Scholar
• Huang X, Ye D, Thorpe PE. Enhancing the potency of a whole-cell breast cancer vaccine in mice with an antibody-IL-2 immunocytokine that targets exposed phosphatidylserine. Vaccine 2011; 29:4785 - 93; http://dx.doi.org/10.1016/j.vaccine.2011.04.082; PMID: 21557977
   PubMed Web of Science ®Google Scholar
• Huynh MLN, Fadok VA, Henson PM. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 2002; 109:41 - 50; PMID: 11781349
   PubMed Web of Science ®Google Scholar
• Zeng Y, Feng HP, Graner MW, Katsanis E. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood 2003; 101:4485 - 91; http://dx.doi.org/10.1182/blood-2002-10-3108; PMID: 12576309
   PubMed Web of Science ®Google Scholar
• Graner MW, Likhacheva A, Davis J, Raymond A, Brandenberger J, Romanoski A, Thompson S, Akporiaye E, Katsanis E. Cargo from tumor-expressed albumin inhibits T-cell activation and responses. Cancer Res 2004; 64:8085 - 92; http://dx.doi.org/10.1158/0008-5472.CAN-04-1871; PMID: 15520220
   PubMed Web of Science ®Google Scholar
• Dong B, Sun L, Wu X, Zhang P, Wang L, Wei H, Zhou L, Hu X, Yu Y, Hua S, et al. Vaccination with TCL plus MHSP65 induces anti-lung cancer immunity in mice. Cancer Immunol Immunother 2010; 59:899 - 908; http://dx.doi.org/10.1007/s00262-010-0816-2; PMID: 20087582
   PubMed Web of Science ®Google Scholar
• Yu JS, Liu GT, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004; 64:4973 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-03-3505; PMID: 15256471
   PubMed Web of Science ®Google Scholar
• Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang AE, Braun TM, Mulé JJ. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001; 61:8513 - 9; PMID: 11731436
   PubMed Web of Science ®Google Scholar
• Höltl L, Zelle-Rieser C, Gander H, Papesh C, Ramoner R, Bartsch G, Rogatsch H, Barsoum AL, Coggin JH Jr., Thurnher M. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 2002; 8:3369 - 76; PMID: 12429623
   PubMed Web of Science ®Google Scholar
• Pandha HS, John RJ, Hutchinson J, James N, Whelan M, Corbishley C, Dalgleish AG. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU Int 2004; 94:412 - 8; http://dx.doi.org/10.1111/j.1464-410X.2004.04922.x; PMID: 15291878
   PubMed Web of Science ®Google Scholar
• Curigliano G, Locatelli M, Fumagalli L, Goldhirsch A. Immunizing against breast cancer: a new swing for an old sword. Breast 2009; 18:Suppl 3 S51 - 4; http://dx.doi.org/10.1016/S0960-9776(09)70273-5; PMID: 19914543
   PubMedGoogle Scholar
• Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Levi J, Daphtary MM, Biedrzycki B, Wolff AC, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 2009; 27:5911 - 8; http://dx.doi.org/10.1200/JCO.2009.23.3494; PMID: 19805669
   PubMed Web of Science ®Google Scholar
• Mehta RS, Schubbert T, Hsiang D, Butler J, Baick C, Su MY. . High pathological complete remission rates with paclitaxel and carboplatin +/− trastuzumab (TC +/− H) following dose dense doxorubicin and cyclophosphamide (AC) supported by GM-CSF in breast cancer-a phase I study. Breast Cancer Research and Treatment2005; 94:S225-S
   Google Scholar
• Meden H, Kuhn W. Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor. Eur J Obstet Gynecol Reprod Biol 1997; 71:173 - 9; http://dx.doi.org/10.1016/S0301-2115(96)02630-9; PMID: 9138962
   PubMed Web of Science ®Google Scholar
• Schiavoni G, Mattei F, Di Pucchio T, Santini SM, Bracci L, Belardelli F, Proietti E. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 2000; 95:2024 - 30; PMID: 10706870
   PubMed Web of Science ®Google Scholar
• Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JPH, Bieler JG, Emens LA, Reilly RT, Jaffee EM. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 2005; 201:1591 - 602; http://dx.doi.org/10.1084/jem.20042167; PMID: 15883172
   PubMed Web of Science ®Google Scholar
• Dols A, Smith JW 2nd, Meijer SL, Fox BA, Hu HM, Walker E, Rosenheim S, Moudgil T, Doran T, Wood W, et al. Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results. Hum Gene Ther 2003; 14:1117 - 23; http://dx.doi.org/10.1089/104303403322124828; PMID: 12885350
   PubMed Web of Science ®Google Scholar
• Jiang XP, Yang DC, Elliott RL, Head JF. Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15-3, CEA and CA125--results in immune and clinical responses in breast cancer patients. Cancer Biother Radiopharm 2000; 15:495 - 505; http://dx.doi.org/10.1089/cbr.2000.15.495; PMID: 11155821
   PubMed Web of Science ®Google Scholar
• Elliott RL, Head JF. Adjuvant breast cancer vaccine improves disease specific survival of breast cancer patients with depressed lymphocyte immunity. Surg Oncol 2013; 22:172 - 7; http://dx.doi.org/10.1016/j.suronc.2013.05.003; PMID: 23791552
   PubMed Web of Science ®Google Scholar
• Raez LE, Cassileth PA, Schlesselman JJ, Sridhar K, Padmanabhan S, Fisher EZ, Baldie PA, Podack ER. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004; 22:2800 - 7; http://dx.doi.org/10.1200/JCO.2004.10.197; PMID: 15254047
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006; 24:4721 - 30; http://dx.doi.org/10.1200/JCO.2005.05.5335; PMID: 16966690
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Nemunaitis M, Senzer N, Snitz P, Bedell C, Kumar P, Pappen B, Maples PB, Shawler D, Fakhrai H. Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther 2009; 16:620 - 4; http://dx.doi.org/10.1038/cgt.2009.15; PMID: 19287371
   PubMed Web of Science ®Google Scholar
• Raez LE, Cassileth PA, Schlesselman JJ, Padmanabhan S, Fisher EZ, Baldie PA, Sridhar K, Podack ER. Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma. Cancer Gene Ther 2003; 10:850 - 8; http://dx.doi.org/10.1038/sj.cgt.7700641; PMID: 14605671
   PubMed Web of Science ®Google Scholar
• Raez L, Walker G, Baldie P, Fisher E, Gomez J, Tolba K, Santos E, Podack E. CD8 T cell response in a phase I study of therapeutic vaccination of advanced NSCLC with allogeneic tumor cells secreting endoplasmic reticulum-chaperone gp96-Ig-peptide complexes. Advances in Lung Cancer 2013; 2:9 - 18; http://dx.doi.org/10.4236/alc.2013.21002
   Google Scholar
• Hus I, Roliński J, Tabarkiewicz J, Wojas K, Bojarska-Junak A, Greiner J, Giannopoulos K, Dmoszyńska A, Schmitt M. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia 2005; 19:1621 - 7; http://dx.doi.org/10.1038/sj.leu.2403860; PMID: 15990861
   PubMed Web of Science ®Google Scholar
• Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB, Garrett-Mayer E, Tsai HL, Qin L, Chia C, et al. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res 2010; 16:338 - 47; http://dx.doi.org/10.1158/1078-0432.CCR-09-2046; PMID: 20048335
   PubMed Web of Science ®Google Scholar
• Morton DL, Hsueh EC, Essner R, Foshag LJ, O’Day SJ, Bilchik A, Gupta RK, Hoon DS, Ravindranath M, Nizze JA, et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 2002; 236:438 - 48, discussion 448-9; http://dx.doi.org/10.1097/00000658-200210000-00006; PMID: 12368672
   PubMed Web of Science ®Google Scholar
• Sondak VK, Sosman JA. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. Semin Cancer Biol 2003; 13:409 - 15; http://dx.doi.org/10.1016/j.semcancer.2003.09.004; PMID: 15001159
   PubMed Web of Science ®Google Scholar
• Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau HY, Lind S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 1988; 48:5883 - 93; PMID: 3262416
   PubMed Web of Science ®Google Scholar
• Vaishampayan U, Abrams J, Darrah D, Jones V, Mitchell MS. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha. Clin Cancer Res 2002; 8:3696 - 701; PMID: 12473578
   PubMed Web of Science ®Google Scholar
• Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA, Thompson JA, Terasaki PI, Sondak VK, Southwest Oncology Group. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 2002; 20:2067 - 75; http://dx.doi.org/10.1200/JCO.2002.08.072; PMID: 11956267
   PubMed Web of Science ®Google Scholar
• Wang F, Bade E, Kuniyoshi C, Spears L, Jeffery G, Marty V, Groshen S, Weber J. Phase I trial of a MART-1 peptide vaccine with incomplete Freund’s adjuvant for resected high-risk melanoma. Clin Cancer Res 1999; 5:2756 - 65; PMID: 10537339
   PubMed Web of Science ®Google Scholar
• von Euw EM, Barrio MM, Furman D, Bianchini M, Levy EM, Yee C, Li Y, Wainstok R, Mordoh J. Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes. J Transl Med 2007; 5:19; http://dx.doi.org/10.1186/1479-5876-5-19; PMID: 17448240
   PubMed Web of Science ®Google Scholar
• Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck J-P, Johnston DA, Fay J, Banchereau J. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother 2006; 29:545 - 57; http://dx.doi.org/10.1097/01.cji.0000211309.90621.8b; PMID: 16971810
   PubMed Web of Science ®Google Scholar
• Michael A, Ball G, Quatan N, Wushishi F, Russell N, Whelan J, Chakraborty P, Leader D, Whelan M, Pandha H. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 2005; 11:4469 - 78; http://dx.doi.org/10.1158/1078-0432.CCR-04-2337; PMID: 15958632
   PubMed Web of Science ®Google Scholar
• Eaton JD, Perry MJA, Nicholson S, Guckian M, Russell N, Whelan M, Kirby RS. Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer. BJU Int 2002; 89:19 - 26; http://dx.doi.org/10.1046/j.1464-410X.2002.02572.x; PMID: 11849155
   PubMed Web of Science ®Google Scholar
• Hrouda D, Souberbielle BE, Kayaga J, Corbishley CM, Kirby RS, Dalgleish AG. Mycobacterium vaccae (SRL172): a potential immunological adjuvant evaluated in rat prostate cancer. Br J Urol 1998; 82:870 - 6; http://dx.doi.org/10.1046/j.1464-410X.1998.00881.x; PMID: 9883227
   PubMedGoogle Scholar
• Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, Nelson WG, Ando D, Howard C, Borellini F, et al. Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007; 13:3883 - 91; http://dx.doi.org/10.1158/1078-0432.CCR-06-2937; PMID: 17606721
   PubMed Web of Science ®Google Scholar
• Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979; 17:16 - 23; PMID: 447482
   PubMedGoogle Scholar
• Montgomery BT, Young CYF, Bilhartz DL, Andrews PE, Prescott JL, Thompson NF, Tindall DJ. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate 1992; 21:63 - 73; http://dx.doi.org/10.1002/pros.2990210107; PMID: 1379363
   PubMed Web of Science ®Google Scholar
• Eager R, Nemunaitis J. GM-CSF gene-transduced tumor vaccines. Mol Ther 2005; 12:18 - 27; http://dx.doi.org/10.1016/j.ymthe.2005.02.012; PMID: 15963916
   PubMed Web of Science ®Google Scholar
• Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman M, Simons JW, Sacks N, Aimi J, Small EJ. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008; 113:975 - 84; http://dx.doi.org/10.1002/cncr.23669; PMID: 18646045
   PubMed Web of Science ®Google Scholar
• Corman JM, Small EJ, Smith DC, Centeno AS, Gittelman M, Steidle CP, et al. Immunotherapy with GVAX((R)) vaccine for prostate cancer improves predicted survival in metastatic hormone refractory prostate cancer: Results from two phase 2 studies.
   Google Scholar
• Lassi K, Dawson NA. Update on castrate-resistant prostate cancer: 2010. Curr Opin Oncol 2010; 22:263 - 7; http://dx.doi.org/10.1097/CCO.0b013e3283380939; PMID: 20177381
   PubMed Web of Science ®Google Scholar
• Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy. Annual Review of Immunology: Annual Reviews {a}, 4139 El Camino Way, Palo Alto, CA, 94303-0139, USA, 2001:565-94.
   Google Scholar
• Nguyen M, Koprivnikar K, Guang H-T, Jooss K, Harding T. Identification of antibody responses induced in patients with metastatic hormone-refractory prostate cancer (HRPC) treated with a GM-CSF-transduced allogeneic prostate cancer immunotherapy (GVAX) and ipilimumab. J Immunother 2007; 30:900
   Web of Science ®Google Scholar
• Pohla H, Brill T, Kuebler H, Buchner A, van Randenborgh H, Paul R, et al. Allogeneic Retrovirally Transduced, IL-2 and IFN-gamma Secreting Tumor Cell Vaccine in Patients With Hormone-Refractory Prostate Cancer (HRPC)-A Phase I/II Trial. J Immunother 2008; 31:947 - 8
   Web of Science ®Google Scholar
• Dodson LF, Hawkins WG, Goedegebuure P. Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy 2011; 3:517 - 37; http://dx.doi.org/10.2217/imt.11.10; PMID: 21463193
   PubMed Web of Science ®Google Scholar
• Laheru D, Biedrzycki B, Thomas AM, Jaffee EM. Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine. In: Su GH, ed. Methods in Molecular Medicine, 2005:299-327.
   Google Scholar
• Middleton G, Ghaneh P, Costello E, Greenhalf W, Neoptolemos JP. New treatment options for advanced pancreatic cancer. Expert Rev Gastroenterol Hepatol 2008; 2:673 - 96; http://dx.doi.org/10.1586/17474124.2.5.673; PMID: 19072345
   PubMedGoogle Scholar
• Galili U, LaTemple DC. Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Immunol Today 1997; 18:281 - 5; http://dx.doi.org/10.1016/S0167-5699(97)80024-2; PMID: 9190114
   PubMedGoogle Scholar
• Macher BA, Galili U. The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochim Biophys Acta 2008; 1780:75 - 88; http://dx.doi.org/10.1016/j.bbagen.2007.11.003; PMID: 18047841
   PubMed Web of Science ®Google Scholar
• LaTemple DC, Henion TR, Anaraki F, Galili U. Synthesis of alpha-galactosyl epitopes by recombinant alpha1,3galactosyl transferase for opsonization of human tumor cell vaccines by anti-galactose. Cancer Res 1996; 56:3069 - 74; PMID: 8674064
   PubMed Web of Science ®Google Scholar
• Hardacre JM, Mulcahy M, Small W, Talamonti M, Obel J, Krishnamurthi S, Rocha-Lima CS, Safran H, Lenz HJ, Chiorean EG. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg 2013; 17:94 - 100, discussion 100-1; http://dx.doi.org/10.1007/s11605-012-2064-6; PMID: 23229886
   PubMed Web of Science ®Google Scholar
• Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, Goemann M, Coleman J, Grochow L, Donehower RC, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001; 19:145 - 56; PMID: 11134207
   PubMed Web of Science ®Google Scholar
• Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 2008; 14:1455 - 63; http://dx.doi.org/10.1158/1078-0432.CCR-07-0371; PMID: 18316569
   PubMed Web of Science ®Google Scholar
• Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, Sugar E, Piantadosi S, Cameron JL, Solt S, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg 2011; 253:328 - 35; http://dx.doi.org/10.1097/SLA.0b013e3181fd271c; PMID: 21217520
   PubMed Web of Science ®Google Scholar
• Habal N, Gupta RK, Bilchik AJ, Yee R, Leopoldo Z, Ye W, Elashoff RM, Morton DL. CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. Ann Surg Oncol 2001; 8:389 - 401; http://dx.doi.org/10.1007/s10434-001-0389-6; PMID: 11407512
   PubMed Web of Science ®Google Scholar
• Westermann J, Flörcken A, Willimsky G, van Lessen A, Kopp J, Takvorian A, Jöhrens K, Lukowsky A, Schönemann C, Sawitzki B, et al. Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study. Gene Ther 2011; 18:354 - 63; http://dx.doi.org/10.1038/gt.2010.143; PMID: 21068778
   PubMed Web of Science ®Google Scholar
• Emens LA, Machiels JP, Reilly RT, Jaffee EM. Chemotherapy: friend or foe to cancer vaccines?. Curr Opin Mol Ther 2001; 3:77 - 84; PMID: 11249735
   PubMed Web of Science ®Google Scholar
• Glöckner S, Buurman H, Kleeberger W, Lehmann U, Kreipe H. Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer. Lab Invest 2002; 82:1419 - 26; http://dx.doi.org/10.1097/01.LAB.0000032371.16521.40; PMID: 12379776
   PubMed Web of Science ®Google Scholar
• Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012; 4:27ps10; http://dx.doi.org/10.1126/scitranslmed.3003854; PMID: 22461637
   PubMed Web of Science ®Google Scholar
• Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al, METABRIC Group. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486:346 - 52; PMID: 22522925
   PubMed Web of Science ®Google Scholar
• Rakha EA, Boyce RWG, Abd El-Rehim D, Kurien T, Green AR, Paish EC, Robertson JF, Ellis IO. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 2005; 18:1295 - 304; http://dx.doi.org/10.1038/modpathol.3800445; PMID: 15976813
   PubMed Web of Science ®Google Scholar
• Springer GF. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med (Berl) 1997; 75:594 - 602; http://dx.doi.org/10.1007/s001090050144; PMID: 9297627
   PubMed Web of Science ®Google Scholar
• Brockhausen I. Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep 2006; 7:599 - 604; http://dx.doi.org/10.1038/sj.embor.7400705; PMID: 16741504
   PubMed Web of Science ®Google Scholar
• Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O’Malley F, Simpson JF, Connolly JL, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124:966 - 78; PMID: 10888772
   PubMed Web of Science ®Google Scholar
• Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005; 54:187 - 207; http://dx.doi.org/10.1007/s00262-004-0560-6; PMID: 15309328
   PubMed Web of Science ®Google Scholar
• Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A, Dohner K, Schlenk RF, Pollack JR, Dohner H, et al. Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. Blood 2006; 108:4109 - 17; http://dx.doi.org/10.1182/blood-2006-01-023127; PMID: 16931630
   PubMed Web of Science ®Google Scholar
• Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999; 5:677 - 85; http://dx.doi.org/10.1038/9525; PMID: 10371507
   PubMed Web of Science ®Google Scholar
• Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008; 44:46 - 53; http://dx.doi.org/10.1016/j.ejca.2007.08.028; PMID: 17945478
   PubMed Web of Science ®Google Scholar
• Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut 2007; 56:1134 - 52; PMID: 17625148
   PubMed Web of Science ®Google Scholar
• Emens LA, Armstrong D, Biedrzycki B, Davidson N, Davis-Sproul J, Fetting J, Jaffee E, Onners B, Piantadosi S, Reilly RT, et al. A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. Hum Gene Ther 2004; 15:313 - 37; http://dx.doi.org/10.1089/104303404322886165; PMID: 15018740
   PubMed Web of Science ®Google Scholar
• Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Levi J, Daphtary MM, Biedrzycki B, Wolff AC, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 2009; 27:5911 - 8; http://dx.doi.org/10.1200/JCO.2009.23.3494; PMID: 19805669
   PubMed Web of Science ®Google Scholar
• Yannelli JR, Sturgill J, Foody T, Hirschowitz E. The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC). Lung Cancer 2005; 47:337 - 50; http://dx.doi.org/10.1016/j.lungcan.2004.08.008; PMID: 15713517
   PubMed Web of Science ®Google Scholar
• Hirschowitz EA, Foody T, Hidalgo GE, Yannelli JR. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer 2007; 57:365 - 72; http://dx.doi.org/10.1016/j.lungcan.2007.04.002; PMID: 17509725
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Jahan T, Ross H, Sterman D, Richards D, Fox B, Jablons D, Aimi J, Lin A, Hege K. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther 2006; 13:555 - 62; http://dx.doi.org/10.1038/sj.cgt.7700922; PMID: 16410826
   PubMed Web of Science ®Google Scholar
• von Euw EM, Barrio MM, Furman D, Levy EM, Bianchini M, Peguillet I, Lantz O, Vellice A, Kohan A, Chacón M, et al. A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression. J Transl Med 2008; 6:6; http://dx.doi.org/10.1186/1479-5876-6-6; PMID: 18221542
   PubMed Web of Science ®Google Scholar
• Mordoh J, Kairiyama C, Bover L, Solarolo E. Allogeneic cells vaccine increases disease-free survival in stage III melanoma patients. A non randomized phase II study. Medicina (B Aires) 1997; 57:421 - 7; PMID: 9674264
   PubMed Web of Science ®Google Scholar
• Barrio MM, de Motta PT, Kaplan J, von Euw EM, Bravo AI, Chacón RD, Mordoh J. A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients. J Immunother 2006; 29:444 - 54; http://dx.doi.org/10.1097/01.cji.0000208258.79005.5f; PMID: 16799340
   PubMed Web of Science ®Google Scholar
• Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B, Borellini F, Clift SM, Hege KM, Ando DG, Piantadosi S, et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Clin Cancer Res 2006; 12:3394 - 401; http://dx.doi.org/10.1158/1078-0432.CCR-06-0145; PMID: 16740763
   PubMed Web of Science ®Google Scholar
• van den Eertwegh AJM, Versluis J, van den Berg HP, Santegoets SJAM, van Moorselaar RJA, van der Sluis TM, Gall HE, Harding TC, Jooss K, Lowy I, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:509 - 17; http://dx.doi.org/10.1016/S1470-2045(12)70007-4; PMID: 22326922
   PubMed Web of Science ®Google Scholar
• Brill TH, Kübler HR, von Randenborgh H, Fend F, Pohla H, Breul J, Hartung R, Paul R, Schendel DJ, Gansbacher B. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial. J Gene Med 2007; 9:547 - 60; http://dx.doi.org/10.1002/jgm.1051; PMID: 17514769
   PubMed Web of Science ®Google Scholar
• Brill TH, Kübler HR, Pohla H, Buchner A, Fend F, Schuster T, van Randenborgh H, Paul R, Kummer T, Plank C, et al. Therapeutic vaccination with an interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial. Hum Gene Ther 2009; 20:1641 - 51; http://dx.doi.org/10.1089/hum.2009.101; PMID: 19671000
   PubMed Web of Science ®Google Scholar